<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03893188</url>
  </required_header>
  <id_info>
    <org_study_id>BASEC-Nr.2018-02015</org_study_id>
    <nct_id>NCT03893188</nct_id>
  </id_info>
  <brief_title>The SwissPrEPared Study</brief_title>
  <official_title>A Multicenter, Observational Cohort to Study the Characteristics of Individuals Asking for Pre-exposure Prophylaxis (PrEP) and the Incidence of HIV and Other Sexually Transmitted Infections: 'The SwissPrEPared Study'</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss HIV Cohort Study</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal Office of Public Health, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Positive Council Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cantonal Hospital St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantonsspital Baselland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nested within the SwissPrEPared Program, the &quot;SwissPrEPared Study&quot; - a large, multicentric,
      nation-wide cohort study - aims to longitudinally follow individuals asking for PrEP
      prescription over a period of 3 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main aims of the study will be:

        1. To obtain epidemiological data on individuals asking for PrEP in Switzerland. We are
           particularly interested in:

             -  Determining the extent of PrEP use in Switzerland;

             -  Assessing and monitoring the occurrence of sexually transmitted infections (STIs)
                in this particular population.

        2. To assess sexual health and sexual well-being in individuals asking for PrEP using a
           questionnaire specifically designed for the SwissPrEPared program.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of individuals asking for PrEP</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of individuals qualifying for PrEP according to current guidelines</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PrEP regime used (daily, intermittent, on-demand)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mode of drug supply (pharmacy versus online)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence rates (to PrEP and to program follow-up)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of side effects</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence and incidence of HIV</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence and incidence of other STIs (syphilis, hepatitis B, hepatitis C, gonorrhoea, chlamydia, mycoplasma genitalium)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>HIV Preexposure Prophylaxis</condition>
  <arm_group>
    <arm_group_label>People asking for PrEP</arm_group_label>
    <description>All individuals aged &gt;18 years asking for PrEP prescription at one of the participating centers will be asked to participate to the SwissPrEPared Study(consecutive ongoing recruitment). Only HIV negative individuals will be deemed eligible.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All individuals aged &gt;18 years asking for PrEP prescription at one of the participating
        centers will be asked to participate to the SwissPrEPared study (consecutive ongoing
        recruitment). Only HIVnegative individuals will be deemed eligible. Participants for whom
        PrEP is not indicated or individuals declining PrEP will still be offered to participate in
        the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participation in the SwissPrEPared program

          -  Aged ≥18 years

          -  HIV negative

        Exclusion Criteria:

          -  Individuals unable to follow program procedures (e.g. language barriers, mental or
             psychiatric disorders)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jan Fehr, Prof.</last_name>
    <phone>+41 44 634 46 11</phone>
    <email>jan.fehr@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benjamin Hampel, MD</last_name>
    <phone>+41 44 634 46 11</phone>
    <email>hansbenjamin.hampel@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Marcel Stoeckle</last_name>
      <email>Marcel.Stoeckle@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Ticcino</name>
      <address>
        <city>Lugano</city>
        <state>Ticcino</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Enos Bernasconi, Prof</last_name>
      <email>enos.bernasconi@eoc.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Laussane</name>
      <address>
        <city>Lausanne</city>
        <state>Waadt</state>
        <zip>1005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Matthias Cavassini, Prof</last_name>
      <email>Matthias.Cavassini@chuv.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Checkpoint Lausanne</name>
      <address>
        <city>Lausanne</city>
        <state>Waadt</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Vanessa Christinet, MD</last_name>
      <email>Vanessa.Christinet@profa.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Checkpoint Bern</name>
      <address>
        <city>Bern</city>
        <zip>3007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Christoph Hauser, MD</last_name>
      <email>Christoph.Hauser@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Christoph Hauser, MD</last_name>
      <email>Christoph.Hauser@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexadnra Calmy, Prof</last_name>
      <email>Alexandra.Calmy@hcuge.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Checkpoint Geneva</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Victor Pecoul</last_name>
      <email>Victor.Pecoul@groupesida.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonspital St. Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Pietro Vernazza, Prof</last_name>
      <email>pietro.vernazza@kssg.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Kalkbreite</name>
      <address>
        <city>Zürich</city>
        <zip>8004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Carsten Depmeier</last_name>
      <email>carsten.depmeier@arztpraxiskalkbreite.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Checkpoint Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Benjamin Hampel, MD</last_name>
      <phone>+41 44 634 46 11</phone>
      <email>benjamin.hampel@checkpoint-zh.ch</email>
    </contact>
    <investigator>
      <last_name>Benjamin Hampel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in the study protocol (including the statistical plan) will be available after de-identification of participants following article publication. Data will be provided to investigators whose proposed use of the data has been approved by the study team and the Scientific Board of the Swiss HIV Cohort Study. Proposals should be directed to jan.fehr@usz.ch.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT03893188/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

